Lord Jenny, Baralle Diana
School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Wessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Front Genet. 2021 Jul 1;12:689892. doi: 10.3389/fgene.2021.689892. eCollection 2021.
Mutations which affect splicing are significant contributors to rare disease, but are frequently overlooked by diagnostic sequencing pipelines. Greater ascertainment of pathogenic splicing variants will increase diagnostic yields, ending the diagnostic odyssey for patients and families affected by rare disorders, and improving treatment and care strategies. Advances in sequencing technologies, predictive modeling, and understanding of the mechanisms of splicing in recent years pave the way for improved detection and interpretation of splice affecting variants, yet several limitations still prohibit their routine ascertainment in diagnostic testing. This review explores some of these advances in the context of clinical application and discusses challenges to be overcome before these variants are comprehensively and routinely recognized in diagnostics.
影响剪接的突变是罕见病的重要成因,但在诊断测序流程中常常被忽视。更多地确定致病性剪接变异将提高诊断率,结束受罕见疾病影响的患者及其家庭的诊断之旅,并改善治疗和护理策略。近年来,测序技术、预测模型以及对剪接机制的理解取得了进展,为改进对影响剪接变异的检测和解读铺平了道路,但仍有一些限制因素阻碍它们在诊断测试中得到常规确定。本综述在临床应用的背景下探讨了其中一些进展,并讨论了在这些变异能够在诊断中得到全面且常规的识别之前需要克服的挑战。